Clear All
777 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Cabozantinib Cabometyx 60 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
J1720 Hydrocortisone Sodium Succinate Cortef, Solu-CORTEF 100 mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid No 1952 Jan 1, 1997 In Use
J1627 Granisetron Hydrochloride Extended Release Granisol [DSC], Sancuso, Sustol, Kytril 0.1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2016 Jan 1, 2018 In Use
Q2055 Idecabtagene vicleucel Abecma 460 million Immunotherapy CAR-T BCMA No 2021 Jan 26, 2022 In Use
Infigratinib Truseltiq Multiple Chemotherapy Tyrosine Kinase Inhibitor FGFR Yes 2021 In Use
NA ixazomib Ninlaro 3 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
J9209 Mesna Mesna rescue, Mesnex, Mesna Novaplus, Uromitexan 200 mg Ancillary Therapy Chemoprotective Detoxifying Agent No 1988 Jan 1, 1990 In Use
NA Crizotinib Xalkori 200 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
NA Ceritinib Zykadia 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2014 In Use
J1952 Leuprolide Mesylate Camcevi 1mg Hormonal Therapy GnRH Agonist No 2021 Jan 26, 2022 In Use
S2107 Immunotherapy - non specific Adoptive immunotherapy (ie development of specific anti-tumor reactivity) NA Immunotherapy No Apr 1, 2002 In Use
C9472 Talimogene Laherparepvec Imlygic 1 million plaque forming unites (PFU) Immunotherapy Therapeutic Cancer Vaccine Oncolytic Virus No 2015 Apr 1, 2016 In Use
J9282 Mitomycin Intravesical Instillation Zusduri 1mg Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin No 2025 Jan 1, 2026 In Use
NA Nilotinib Tasigna 150 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Capmatinib Tabrecta 150mg, 200mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2020 In Use
NA Sorafenib Nexavar 200 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET, CRAF, BRAF Yes 2005 In Use
NA Sotorasib Lumakras Multiple Chemotherapy RAS Inhibitor KRASG12C Yes 2021 In Use
J9347 Tremelimumab-actl Imjudo 1mg Immunotherapy Monoclonal Antibody CTLA-4 No 2022 Jul 11, 2023 In Use
J7512 Prednisone Deltasone, PredniSONE Intensol, Rayos 1 mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Yes 1974 Jan 1, 2016 In Use
NA Midostaurin Rydapt 25 mg Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2017 In Use
Mobocertinib Exkivity 40mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2021 In Use
NA Dabrafenib Tafinlar 75 mg Chemotherapy Tyrosine Kinase Inhibitor BRAF Yes 2013 Jan 1, 2004 In Use
Pacritinib Vonjo 100mg Chemotherapy Tyrosine Kinase Inhibitor JAK2, FLT3 Yes 2022 In Use
NA Dasatinib Sprycel 50 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
J9049 Bortezomib (Hospira) Bortezomib (Hospira) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2022 Dec 21, 2022 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.